Fig. 3.

Oncoplot of available tissue data with overall survival (OS) after surgery in different patient groups in the patient cohort. A: Consecutive patients are listed horizontally in chronological order (time of surgery from 2017 to 2022). NGS = Next-generation sequencing. mTOR-P-IHC = Phospho-mTOR Immunohistochemistry. IDH = isocitrate dehydrogenase. CDK4/6i = Cycline-dependent Kinase 4/6 inhibitors. mTORi = mammalian target of rapamycin inhibitor. PARPi = Poly (ADP-ribose) polymerase inhibitor. MEKi = Mitogen-activated protein kinase kinase inhibitor. GTR = Gross Total Resection, STR = Subtotal resection B: All patients in the cohort (median survival 399 days). C: Survival after surgery based on WHO classification grades (WHO 2: undefined, WHO 3: undefined, WHO 4, isocitrate dehydrogenase wild type, IDH-WT: 334 days, WHO 4, IDH-mut: 197 days. D: Survival in GBM, IDH-WT patients after gross total resection (GTR, 348 days) vs all other surgical modalities (subtotal resection – STR and biopsies, survival undefined) in this cohort, p = 0.04, Gehan-Breslow-Wilcoxon test